Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 8/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4991624 | 0.93 | MTTP (0.50) | MTTPRXFP1DHODHNPC1RAB9A | |
| SCHEMBL4989274 | 0.92 | MTTP (0.46) | MTTPDHODHNPC1RAB9A | |
| SCHEMBL4984087 | 0.91 | MTTP (0.50) | MTTPRXFP1NPC1RAB9A | |
| SCHEMBL4985584 | 0.88 | RXFP1 (0.48) | MTTPRXFP1NPC1RAB9AMAPT | |
| SCHEMBL4981792 | 0.87 | MTTP (0.57) | MTTPDHODH | |
| SCHEMBL4989401 | 0.84 | MTTP (0.51) | MTTPTP53 | |
| SCHEMBL4986717 | 0.84 | MTTP (0.48) | MTTPDHODH | |
| SCHEMBL4986116 | 0.83 | MTTP (0.48) | MTTPMAPT | |
| SCHEMBL4981516 | 0.82 | MTTP (0.59) | MTTPDHODH | |
| SCHEMBL4990333 | 0.81 | MTTP (0.51) | MTTPRXFP1NPC1RAB9ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468378-B2 | Substituted quinoline compounds | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| EP-1716137-A1 | SUBSTITUTED QUINOLINE COMPOUNDS | Pfizer Products Incorporated (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
| US-20050234099-A1 | Substituted quinoline compounds | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| WO-2005080373-A1 | SUBSTITUTED QUINOLINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234099-A1 | Substituted quinoline compounds | APOB, APOL1, MTPN | MTTP 9/4885RXFP1 735/4885DHODH 2036/4885 |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | MTTP 7/4885RXFP1 1082/4885DHODH 3120/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | MTTP 7/4885RXFP1 1082/4885DHODH 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.